Loading...
XSHE
300318
Market cap788mUSD
Dec 05, Last price  
6.82CNY
1D
0.59%
1Q
16.38%
Jan 2017
-24.72%
IPO
140.46%
Name

Beijing Bohui Innovation Biotechnology Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300318 chart
P/E
602.56
P/S
6.54
EPS
0.01
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
6.27%
Revenues
852m
-18.53%
25,875,88029,366,27139,398,13751,462,66363,583,36878,406,66098,121,947113,760,681106,870,485100,969,495268,846,009404,048,600443,754,419622,093,848628,340,031738,717,388714,748,462795,932,4951,045,429,099851,694,578
Net income
9m
P
13,917,59012,954,76122,297,46539,854,41225,911,98633,743,60644,776,08150,954,46654,256,73338,138,79411,882,00823,599,15238,850,99069,438,2862,542,7557,503,97600-24,929,3919,245,978
CFO
-39m
L
9,401,34623,297,46916,040,74922,785,85132,232,68346,893,66361,282,91255,081,30931,048,91188,950,52277,969,56500086,137,577887,77740,718,935137,017,197-38,691,051
Dividend
Jul 12, 20180.005012 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Beijing Bohui Innovation Biotechnology Group Co., Ltd. engages in the research and development, production, sale, and after-sale service of diagnostic products in China. It offers GenPlex, a microfluidic automated nucleic acid detection system, immunofluorescence detection products, and human trace element detection products; and chemical analysis products, such as atomic fluorescence spectrometer and photometer, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, life sciences related consumables, and ICP spectroscopy. The company was formerly known as Beijing Bohui Innovation Biotechnology Co., Ltd. and changed its name to Beijing Bohui Innovation Biotechnology Group Co., Ltd. in August 2021. Beijing Bohui Innovation Biotechnology Group Co., Ltd. was founded in 2001 and is headquartered in Beijing, China.
IPO date
May 23, 2012
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT